ProfileGDS5678 / 1460254_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 51% 51% 51% 51% 54% 52% 59% 51% 50% 51% 52% 44% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0901445
GSM967853U87-EV human glioblastoma xenograft - Control 23.2220751
GSM967854U87-EV human glioblastoma xenograft - Control 33.2235851
GSM967855U87-EV human glioblastoma xenograft - Control 43.1594551
GSM967856U87-EV human glioblastoma xenograft - Control 53.1709751
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4258954
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3369752
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5386859
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2124351
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1876150
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2082351
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2293152
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.018344
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2113251